Tumors in three of the mouse models (OE19, N87CLDN18.2, and PANC 05.04) showed rapid regression upon TAC01-CLDN18.2 treatment, leading to complete tumor clearance that was achieved 24 days after adoptive cell transfer (ACT) or earlier (Fig. 5A; Supplementary Table S6). The gene discussed is CLDN18; the disease is neoplasm.